AbbVie swings to Q4 loss amid Cerevel impact; sets in-line guidance
AbbVie (NYSE:ABBV) traded higher in the premarket on Friday after setting its 2025 earnings outlook in line with expectations ...
Hosted on MSN3h
AbbVie (NYSE:ABBV) Posts Better-Than-Expected Sales In Q4, Stock Soars
Pharmaceutical company AbbVie (NYSE:ABBV) reported Q4 CY2024 results , with sales up 5.6% year on year to $15.1 billion. Its non-GAAP profit of $2.16 per share was 4.3% below analysts’ consensus ...
AbbVie Jumps After Q4 Earnings Beat, Skyrizi And Rinvoq Boom Offsets Humira Decline
AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue ...
AbbVie reports Q4 adjusted EPS $2.16, consensus $2.26
Reports Q4 revenue $15.1B, consensus $14.83B. “2024 was a year of significant progress for AbbVie (ABBV). Our growth platform delivered ...
Why ABBV Is Rallying Today
AbbVie (ABBV), a large drug maker, is jumping 8% after the company provided significantly higher-than-expected 2025 earnings ...
William Blair Has Negative Outlook of AbbVie FY2024 Earnings
William Blair reduced their FY2024 EPS estimates for shares of AbbVie in a research note issued on Tuesday, January 21st.